Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
TUSC5 regulates insulin-mediated adipose tissue glucose uptake by modulation of GLUT4 recycling.

Molecular metabolism

Beaton N, Rudigier C, Moest H, Müller S, Mrosek N, Röder E, Rudofsky G, Rülicke T, Ukropec J, Ukropcova B, Augustin R, Neubauer H, Wolfrum C.
PMID: 26629404
Mol Metab. 2015 Aug 28;4(11):795-810. doi: 10.1016/j.molmet.2015.08.003. eCollection 2015 Nov.

OBJECTIVE: Failure to properly dispose of glucose in response to insulin is a serious health problem, occurring during obesity and is associated with type 2 diabetes development. Insulin-stimulated glucose uptake is facilitated by the translocation and plasma membrane fusion...

Cite
Beaton N, Rudigier C, Moest H, et al. TUSC5 regulates insulin-mediated adipose tissue glucose uptake by modulation of GLUT4 recycling. Mol Metab. 2015;4(11):795-810doi: 10.1016/j.molmet.2015.08.003.
Beaton, N., Rudigier, C., Moest, H., Müller, S., Mrosek, N., Röder, E., Rudofsky, G., Rülicke, T., Ukropec, J., Ukropcova, B., Augustin, R., Neubauer, H., & Wolfrum, C. (2015). TUSC5 regulates insulin-mediated adipose tissue glucose uptake by modulation of GLUT4 recycling. Molecular metabolism, 4(11), 795-810. https://doi.org/10.1016/j.molmet.2015.08.003
Beaton, Nigel, et al. "TUSC5 regulates insulin-mediated adipose tissue glucose uptake by modulation of GLUT4 recycling." Molecular metabolism vol. 4,11 (2015): 795-810. doi: https://doi.org/10.1016/j.molmet.2015.08.003
Beaton N, Rudigier C, Moest H, Müller S, Mrosek N, Röder E, Rudofsky G, Rülicke T, Ukropec J, Ukropcova B, Augustin R, Neubauer H, Wolfrum C. TUSC5 regulates insulin-mediated adipose tissue glucose uptake by modulation of GLUT4 recycling. Mol Metab. 2015 Aug 28;4(11):795-810. doi: 10.1016/j.molmet.2015.08.003. eCollection 2015 Nov. PMID: 26629404; PMCID: PMC4632119.
Copy Download .nbib Format: NLM
Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants.

Movement disorders clinical practice

Deck BL, Xie SX, Choi G, Rick J, Siderowf A, Rudovsky S, Chen-Plotkin A, Duda JE, Morley JF, Dahodwala N, Trojanowski JQ, Weintraub D.
PMID: 31392244
Mov Disord Clin Pract. 2019 May 17;6(6):440-445. doi: 10.1002/mdc3.12781. eCollection 2019 Jul.

BACKGROUND: The Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) assesses cognition-related instrumental activities of daily living (IADL) in Parkinson's disease (PD).OBJECTIVES: To assess the degree and predictors of disagreement between patients (PT) and knowledgeable informants (KI) on the PDAQ-15.METHODS: We...

Cite
Deck BL, Xie SX, Choi G, et al. Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. Mov Disord Clin Pract. 2019;6(6):440-445doi: 10.1002/mdc3.12781.
Deck, B. L., Xie, S. X., Choi, G., Rick, J., Siderowf, A., Rudovsky, S., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Dahodwala, N., Trojanowski, J. Q., & Weintraub, D. (2019). Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. Movement disorders clinical practice, 6(6), 440-445. https://doi.org/10.1002/mdc3.12781
Deck, Benjamin L, et al. "Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants." Movement disorders clinical practice vol. 6,6 (2019): 440-445. doi: https://doi.org/10.1002/mdc3.12781
Deck BL, Xie SX, Choi G, Rick J, Siderowf A, Rudovsky S, Chen-Plotkin A, Duda JE, Morley JF, Dahodwala N, Trojanowski JQ, Weintraub D. Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. Mov Disord Clin Pract. 2019 May 17;6(6):440-445. doi: 10.1002/mdc3.12781. eCollection 2019 Jul. PMID: 31392244; PMCID: PMC6660222.
Copy Download .nbib Format: NLM
[No title available]

Praxis

Brönnimann A, Rudofsky G, Paganoni R, Studhalter M.
PMID: 29231088
Praxis (Bern 1994). 2017;106(25):1397-1400. doi: 10.1024/1661-8157/a002849.

No abstract available.

Cite
Brönnimann A, Rudofsky G, Paganoni R, et al. Wenn die Therapie den Patienten bedroht. . Praxis (Bern 1994). 2017;106(25):1397-1400doi: 10.1024/1661-8157/a002849.
Brönnimann, A., Rudofsky, G., Paganoni, R., & Studhalter, M. (2017). Wenn die Therapie den Patienten bedroht. . Praxis, 106(25), 1397-1400. https://doi.org/10.1024/1661-8157/a002849
Brönnimann, Alain, et al. "Wenn die Therapie den Patienten bedroht." . Praxis vol. 106,25 (2017): 1397-1400. doi: https://doi.org/10.1024/1661-8157/a002849
Brönnimann A, Rudofsky G, Paganoni R, Studhalter M. Wenn die Therapie den Patienten bedroht. . Praxis (Bern 1994). 2017;106(25):1397-1400. doi: 10.1024/1661-8157/a002849. German. PMID: 29231088.
Copy Download .nbib Format: NLM
Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma - Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes.

Frontiers in oncology

Bogowicz M, Pavic M, Riesterer O, Finazzi T, Garcia Schüler H, Holz-Sapra E, Rudofsky L, Basler L, Spaniol M, Ambrusch A, Hüllner M, Guckenberger M, Tanadini-Lang S.
PMID: 34123824
Front Oncol. 2021 May 27;11:664304. doi: 10.3389/fonc.2021.664304. eCollection 2021.

PURPOSE: Radiomics has already been proposed as a prognostic biomarker in head and neck cancer (HNSCC). However, its predictive power in radiotherapy has not yet been studied. Here, we investigated a local radiomics approach to distinguish between tumor sub-volumes...

Cite
Bogowicz M, Pavic M, Riesterer O, et al. Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma - Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes. Front Oncol. 2021;11:664304doi: 10.3389/fonc.2021.664304.
Bogowicz, M., Pavic, M., Riesterer, O., Finazzi, T., Garcia Schüler, H., Holz-Sapra, E., Rudofsky, L., Basler, L., Spaniol, M., Ambrusch, A., Hüllner, M., Guckenberger, M., & Tanadini-Lang, S. (2021). Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma - Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes. Frontiers in oncology, 11664304. https://doi.org/10.3389/fonc.2021.664304
Bogowicz, Marta, et al. "Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma - Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes." Frontiers in oncology vol. 11 (2021): 664304. doi: https://doi.org/10.3389/fonc.2021.664304
Bogowicz M, Pavic M, Riesterer O, Finazzi T, Garcia Schüler H, Holz-Sapra E, Rudofsky L, Basler L, Spaniol M, Ambrusch A, Hüllner M, Guckenberger M, Tanadini-Lang S. Targeting Treatment Resistance in Head and Neck Squamous Cell Carcinoma - Proof of Concept for CT Radiomics-Based Identification of Resistant Sub-Volumes. Front Oncol. 2021 May 27;11:664304. doi: 10.3389/fonc.2021.664304. eCollection 2021. PMID: 34123824; PMCID: PMC8191457.
Copy Download .nbib Format: NLM
Impact of Albumin-to-Creatinine Ratio Point-of-Care Testing on the Diagnosis and Management of Diabetic Kidney Disease.

Journal of diabetes science and technology

Schultes B, Emmerich S, Kistler AD, Mecheri B, Schnell O, Rudofsky G.
PMID: 34709065
J Diabetes Sci Technol. 2021 Oct 28;19322968211054520. doi: 10.1177/19322968211054520. Epub 2021 Oct 28.

BACKGROUND: For the diagnosis of diabetic kidney disease (DKD), quantitative albuminuria measurement using the albumin-to-creatinine ratio (ACR) is recommended according to various guidelines. It can be measured either in specialized laboratories or using ACR point-of-care testing (POCT). This observational...

Cite
Schultes B, Emmerich S, Kistler AD, et al. Impact of Albumin-to-Creatinine Ratio Point-of-Care Testing on the Diagnosis and Management of Diabetic Kidney Disease. J Diabetes Sci Technol. 2021;19322968211054520doi: 10.1177/19322968211054520.
Schultes, B., Emmerich, S., Kistler, A. D., Mecheri, B., Schnell, O., & Rudofsky, G. (2021). Impact of Albumin-to-Creatinine Ratio Point-of-Care Testing on the Diagnosis and Management of Diabetic Kidney Disease. Journal of diabetes science and technology, 19322968211054520. https://doi.org/10.1177/19322968211054520
Schultes, Bernd, et al. "Impact of Albumin-to-Creatinine Ratio Point-of-Care Testing on the Diagnosis and Management of Diabetic Kidney Disease." Journal of diabetes science and technology vol. (2021): 19322968211054520. doi: https://doi.org/10.1177/19322968211054520
Schultes B, Emmerich S, Kistler AD, Mecheri B, Schnell O, Rudofsky G. Impact of Albumin-to-Creatinine Ratio Point-of-Care Testing on the Diagnosis and Management of Diabetic Kidney Disease. J Diabetes Sci Technol. 2021 Oct 28;19322968211054520. doi: 10.1177/19322968211054520. Epub 2021 Oct 28. PMID: 34709065.
Copy Download .nbib Format: NLM
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL.
PMID: 34874182
J Clin Oncol. 2022 Jan 20;40(3):282-293. doi: 10.1200/JCO.21.02554. Epub 2021 Dec 07.

PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor-positive breast cancer has not been confirmed.PATIENTS AND METHODS:...

Cite
Gnant M, Dueck AC, Frantal S, et al. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2021;40(3):282-293doi: 10.1200/JCO.21.02554.
Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., Chan, A., Winer, E. P., Pfeiler, G., Miller, K. D., Colleoni, M., Suga, J. M., Rubovsky, G., Bliss, J. M., Mayer, I. A., Singer, C. F., Nowecki, Z., Hahn, O., Thomson, J., Wolmark, N., Amillano, K., Rugo, H. S., Steger, G. G., Hernando Fernández de Aránguiz, B., Haddad, T. C., Perelló, A., Bellet, M., Fohler, H., Metzger Filho, O., Jallitsch-Halper, A., Solomon, K., Schurmans, C., Theall, K. P., Lu, D. R., Tenner, K., Fesl, C., DeMichele, A., Mayer, E. L. (2022). Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(3), 282-293. https://doi.org/10.1200/JCO.21.02554
Gnant, Michael, et al. "Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 40,3 (2022): 282-293. doi: https://doi.org/10.1200/JCO.21.02554
Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022 Jan 20;40(3):282-293. doi: 10.1200/JCO.21.02554. Epub 2021 Dec 07. PMID: 34874182.
Copy Download .nbib Format: NLM
Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance.

Genes & nutrition

Wallmeier D, Winkler JK, Fleming T, Woehning A, Huennemeyer K, Roeder E, Nawroth PP, Friederich HC, Wolfrum C, Schultz JH, Rudofsky G.
PMID: 23797338
Genes Nutr. 2013 Jun 25; doi: 10.1007/s12263-013-0350-x. Epub 2013 Jun 25.

The serotonergic pathway plays a major role in the development of obesity. Its activity can be modulated by the 5-HT transporter-linked polymorphic region in the SLC6A4 gene and the upstream variable number of tandem repeats polymorphism in the MAOA...

Cite
Wallmeier D, Winkler JK, Fleming T, et al. Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance. Genes Nutr. 2013;doi: 10.1007/s12263-013-0350-x.
Wallmeier, D., Winkler, J. K., Fleming, T., Woehning, A., Huennemeyer, K., Roeder, E., Nawroth, P. P., Friederich, H. C., Wolfrum, C., Schultz, J. H., & Rudofsky, G. (2013). Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance. Genes & nutrition, . https://doi.org/10.1007/s12263-013-0350-x
Wallmeier, Dirk, et al. "Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance." Genes & nutrition vol. (2013). doi: https://doi.org/10.1007/s12263-013-0350-x
Wallmeier D, Winkler JK, Fleming T, Woehning A, Huennemeyer K, Roeder E, Nawroth PP, Friederich HC, Wolfrum C, Schultz JH, Rudofsky G. Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance. Genes Nutr. 2013 Jun 25; doi: 10.1007/s12263-013-0350-x. Epub 2013 Jun 25. PMID: 23797338; PMCID: PMC3824832.
Copy Download .nbib Format: NLM
Transcriptional regulation of adipocyte formation by the liver receptor homologue 1 (Lrh1)-Small hetero-dimerization partner (Shp) network.

Molecular metabolism

Mrosek N, Meissburger B, Mataki C, Roeder E, Ukropec J, Klimes I, Gasperikova D, Nawroth PP, Rudofsky G, Auwerx J, Schoonjans K, Wolfrum C.
PMID: 24049743
Mol Metab. 2013 Mar 16;2(3):314-23. doi: 10.1016/j.molmet.2013.03.003. eCollection 2013.

Altered adipose tissue formation is a well-known effectors of obesity and T2D. Here, we describe the role of Lrh1 and its co-repressor Shp in the control of adipocyte formation. Expression of Lrh1 in the pre-adipocyte containing SVF is induced...

Cite
Mrosek N, Meissburger B, Mataki C, et al. Transcriptional regulation of adipocyte formation by the liver receptor homologue 1 (Lrh1)-Small hetero-dimerization partner (Shp) network. Mol Metab. 2013;2(3):314-23doi: 10.1016/j.molmet.2013.03.003.
Mrosek, N., Meissburger, B., Mataki, C., Roeder, E., Ukropec, J., Klimes, I., Gasperikova, D., Nawroth, P. P., Rudofsky, G., Auwerx, J., Schoonjans, K., & Wolfrum, C. (2013). Transcriptional regulation of adipocyte formation by the liver receptor homologue 1 (Lrh1)-Small hetero-dimerization partner (Shp) network. Molecular metabolism, 2(3), 314-23. https://doi.org/10.1016/j.molmet.2013.03.003
Mrosek, Nadja, et al. "Transcriptional regulation of adipocyte formation by the liver receptor homologue 1 (Lrh1)-Small hetero-dimerization partner (Shp) network." Molecular metabolism vol. 2,3 (2013): 314-23. doi: https://doi.org/10.1016/j.molmet.2013.03.003
Mrosek N, Meissburger B, Mataki C, Roeder E, Ukropec J, Klimes I, Gasperikova D, Nawroth PP, Rudofsky G, Auwerx J, Schoonjans K, Wolfrum C. Transcriptional regulation of adipocyte formation by the liver receptor homologue 1 (Lrh1)-Small hetero-dimerization partner (Shp) network. Mol Metab. 2013 Mar 16;2(3):314-23. doi: 10.1016/j.molmet.2013.03.003. eCollection 2013. PMID: 24049743; PMCID: PMC3773829.
Copy Download .nbib Format: NLM
No short-term effects of calorie-controlled Mediterranean or fast food dietary interventions on established biomarkers of vascular or metabolic risk in healthy individuals.

Nutrition research and practice

Parcina M, Brune M, Kaese V, Zorn M, Spiegel R, Vojvoda V, Fleming T, Rudofsky G, Paul Nawroth P.
PMID: 25861423
Nutr Res Pract. 2015 Apr;9(2):165-73. doi: 10.4162/nrp.2015.9.2.165. Epub 2014 Dec 10.

BACKGROUND/OBJECTIVES: This study addressed the question whether the composition of supposedly 'healthy' or 'unhealthy' dietary regimes has a calorie-independent short-term effect on biomarkers of metabolic stress and vascular risk in healthy individuals.SUBJECTS/METHODS: Healthy male volunteers (age 29.5 ± 5.9...

Cite
Parcina M, Brune M, Kaese V, et al. No short-term effects of calorie-controlled Mediterranean or fast food dietary interventions on established biomarkers of vascular or metabolic risk in healthy individuals. Nutr Res Pract. 2014;9(2):165-73doi: 10.4162/nrp.2015.9.2.165.
Parcina, M., Brune, M., Kaese, V., Zorn, M., Spiegel, R., Vojvoda, V., Fleming, T., Rudofsky, G., & Paul Nawroth, P. (2015). No short-term effects of calorie-controlled Mediterranean or fast food dietary interventions on established biomarkers of vascular or metabolic risk in healthy individuals. Nutrition research and practice, 9(2), 165-73. https://doi.org/10.4162/nrp.2015.9.2.165
Parcina, Marijo, et al. "No short-term effects of calorie-controlled Mediterranean or fast food dietary interventions on established biomarkers of vascular or metabolic risk in healthy individuals." Nutrition research and practice vol. 9,2 (2015): 165-73. doi: https://doi.org/10.4162/nrp.2015.9.2.165
Parcina M, Brune M, Kaese V, Zorn M, Spiegel R, Vojvoda V, Fleming T, Rudofsky G, Paul Nawroth P. No short-term effects of calorie-controlled Mediterranean or fast food dietary interventions on established biomarkers of vascular or metabolic risk in healthy individuals. Nutr Res Pract. 2015 Apr;9(2):165-73. doi: 10.4162/nrp.2015.9.2.165. Epub 2014 Dec 10. PMID: 25861423; PMCID: PMC4388948.
Copy Download .nbib Format: NLM
Nanotubes from chalcogenide misfit compounds: Sn-S and Nb-Pb-S.

Accounts of chemical research

Radovsky G, Popovitz-Biro R, Stroppa DG, Houben L, Tenne R.
PMID: 24044507
Acc Chem Res. 2014 Feb 18;47(2):406-16. doi: 10.1021/ar400138h. Epub 2013 Sep 17.

Carbon fullerenes and nanotubes revolutionized understandingof the reactivity of nanoscale compounds. Subsequently, our group and others discovered analogous inorganic compounds with hollow, closed nanostructures. Such inorganic nanostructures offer many applications, particularly in the energy and electronics industries. One way...

Cite
Radovsky G, Popovitz-Biro R, Stroppa DG, et al. Nanotubes from chalcogenide misfit compounds: Sn-S and Nb-Pb-S. Acc Chem Res. 2013;47(2):406-16doi: 10.1021/ar400138h.
Radovsky, G., Popovitz-Biro, R., Stroppa, D. G., Houben, L., & Tenne, R. (2014). Nanotubes from chalcogenide misfit compounds: Sn-S and Nb-Pb-S. Accounts of chemical research, 47(2), 406-16. https://doi.org/10.1021/ar400138h
Radovsky, Gal, et al. "Nanotubes from chalcogenide misfit compounds: Sn-S and Nb-Pb-S." Accounts of chemical research vol. 47,2 (2014): 406-16. doi: https://doi.org/10.1021/ar400138h
Radovsky G, Popovitz-Biro R, Stroppa DG, Houben L, Tenne R. Nanotubes from chalcogenide misfit compounds: Sn-S and Nb-Pb-S. Acc Chem Res. 2014 Feb 18;47(2):406-16. doi: 10.1021/ar400138h. Epub 2013 Sep 17. PMID: 24044507.
Copy Download .nbib Format: NLM
[Not Available].

Praxis

Rudofsky L, Holz-Sapra E.
PMID: 27524172
Praxis (Bern 1994). 2016 Aug;105(16):982. doi: 10.1024/1661-8157/a002421.

No abstract available.

Cite
Rudofsky L, Holz-Sapra E. CME-Antworten zu den Fragen zu «Strahlentherapie bei nicht-onkologischen Erkrankungen» aus Praxis Nr. 15. [Not Available]. Praxis (Bern 1994). 2016;105(16):982doi: 10.1024/1661-8157/a002421.
Rudofsky, L., & Holz-Sapra, E. (2016). CME-Antworten zu den Fragen zu «Strahlentherapie bei nicht-onkologischen Erkrankungen» aus Praxis Nr. 15. [Not Available]. Praxis, 105(16), 982. https://doi.org/10.1024/1661-8157/a002421
Rudofsky, Leonie, and Holz-Sapra, Edna. "CME-Antworten zu den Fragen zu «Strahlentherapie bei nicht-onkologischen Erkrankungen» aus Praxis Nr. 15." [Not Available]. Praxis vol. 105,16 (2016): 982. doi: https://doi.org/10.1024/1661-8157/a002421
Rudofsky L, Holz-Sapra E. CME-Antworten zu den Fragen zu «Strahlentherapie bei nicht-onkologischen Erkrankungen» aus Praxis Nr. 15. [Not Available]. Praxis (Bern 1994). 2016 Aug;105(16):982. doi: 10.1024/1661-8157/a002421. German. PMID: 27524172.
Copy Download .nbib Format: NLM
Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Hepprich M, Zillig D, Florian-Reynoso MA, Donath MY, Rudofsky G.
PMID: 33615400
Diabetes Ther. 2021 Mar;12(3):943-954. doi: 10.1007/s13300-021-01016-y. Epub 2021 Feb 22.

INTRODUCTION: Despite expert consensus guidelines, data is scarce on how to switch patients with type 2 diabetes when treatment with glucagon-like peptide 1 (GLP-1) receptor agonists is not effective and whether a switch to semaglutide brings any benefit on...

Cite
Hepprich M, Zillig D, Florian-Reynoso MA, et al. Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. Diabetes Ther. 2021;12(3):943-954doi: 10.1007/s13300-021-01016-y.
Hepprich, M., Zillig, D., Florian-Reynoso, M. A., Donath, M. Y., & Rudofsky, G. (2021). Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. Diabetes therapy : research, treatment and education of diabetes and related disorders, 12(3), 943-954. https://doi.org/10.1007/s13300-021-01016-y
Hepprich, Matthias, et al. "Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 12,3 (2021): 943-954. doi: https://doi.org/10.1007/s13300-021-01016-y
Hepprich M, Zillig D, Florian-Reynoso MA, Donath MY, Rudofsky G. Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. Diabetes Ther. 2021 Mar;12(3):943-954. doi: 10.1007/s13300-021-01016-y. Epub 2021 Feb 22. PMID: 33615400; PMCID: PMC7947039.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries